Umeclidinium 0.0625 mg/ACTUAT / vilanterol 0.025 mg/ACTUAT [Anoro]
RxNorm 1487521

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1487521 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: umeclidinium 0.0625 mg/ACTUAT / vilanterol 0.025 mg/ACTUAT [Anoro].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Umeclidinium 0.0625 mg/ACTUAT / vilanterol 0.025 mg/ACTUAT [Anoro]
AUI:5940812
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Umeclidinium 0.0625 mg/ACTUAT / vilanterol 0.025 mg/ACTUAT [Anoro]
(Atom ID: 5940812)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT [Anoro]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1487521
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
5940812
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
1487521
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Umeclidinium and Vilanterol Oral Inhalation


The combination of umeclidinium and vilanterol is used to control wheezing, shortness of breath, coughing, and chest tightness caused by chronic obstructive pulmonary disease (COPD; a group of diseases that affect the lungs and airways, which includes chronic bronchitis and emphysema). Umeclidinium is in a class of medications called anticholinergics. Vilanterol is in a class of medications called long-acting beta-agonists (LABAs). These medications work by relaxing and opening air passages in the lungs, making it easier to breathe.
[Learn More]


* Please review the disclaimer below.